SCHEDULE 13G/A: HBM Healthcare Investments Amends IO Biotech Stake Disclosure, Including Warrants

HBM Healthcare Investments (Cayman) Ltd. has filed an amended Schedule 13G, correcting its beneficial ownership in IO Biotech, Inc. to include 1,578,947 shares from warrants, bringing its total stake to 8.2% as of December 31, 2023.

Summary

• HBM Healthcare Investments (Cayman) Ltd. filed an Amendment No. 4 to its Schedule 13G for IO Biotech, Inc.
• The amendment corrects a previous filing from February 13, 2024, which inadvertently excluded warrants from the beneficial ownership calculation.
• As of December 31, 2023, HBM Healthcare Investments beneficially owns 5,523,439 shares of IO Biotech, Inc. Common Stock.
• This total includes 3,944,492 shares of Common Stock and 1,578,947 shares acquirable within 60 days upon exercise of warrants.
• The warrants have an exercise price of $2.47 per share and are subject to a 9.99% beneficial ownership limitation.
• The aggregate beneficial ownership represents 8.2% of IO Biotech, Inc.'s outstanding Common Stock.
• The percentage is calculated based on 65,880,914 shares outstanding as of November 8, 2024 (per Issuer's 10-Q) plus the 1,578,947 warrant shares.
• HBM Healthcare Investments (Cayman) Ltd. has sole voting and dispositive power over these shares.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily a factual correction of a beneficial ownership filing. The continued significant stake by a healthcare investment firm is mildly positive, but the administrative error in the previous filing is a minor negative. Overall, it's a standard regulatory update with no major positive or negative operational news.

Positives

• A significant institutional investor, HBM Healthcare Investments, maintains a substantial stake (8.2%) in IO Biotech, Inc., indicating continued confidence.
• The correction of the filing demonstrates transparency and adherence to regulatory requirements.

Negatives

• The previous filing error (inadvertent exclusion of warrants) could suggest minor administrative oversight, though it has been corrected.

Risks

• The warrants are subject to a 9.99% beneficial ownership limitation, which could restrict HBM Healthcare Investments' ability to fully exercise them if it would exceed this threshold.
• The value of the warrant shares is dependent on the stock price exceeding the $2.47 exercise price.

Future Outlook

The document does not contain forward-looking statements or guidance regarding IO Biotech, Inc.'s future performance or strategic direction. It solely pertains to an update on beneficial ownership by HBM Healthcare Investments (Cayman) Ltd.

Management Comments

• "This Schedule 13G/A is being filed solely to correct the Schedule 13G/A that the Reporting Person filed on February 13, 2024, which inadvertently excluded the Warrants (as defined herein) from the Reporting Person's beneficial ownership."
• "Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the 'Board'). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares."

Industry Context

This filing is a routine disclosure of a significant institutional investor's stake in a biotechnology company. Such filings are common in the biotech sector, where strategic investments by specialized healthcare funds like HBM Healthcare Investments are frequent. It indicates continued institutional interest in IO Biotech, Inc., a company likely involved in drug development or related healthcare innovations, given its CUSIP and the nature of the investor.

Stakeholder Impact

• Shareholders: Provides updated information on a significant institutional holder's stake, confirming their continued investment.
• Management: No direct impact on management, but awareness of major shareholders is always relevant.
• Employees, Customers, Suppliers, Creditors: No direct impact mentioned in this filing.

Next Steps

• IO Biotech, Inc. will continue to operate its business.
• HBM Healthcare Investments (Cayman) Ltd. will continue to hold its stake in IO Biotech, Inc.
• Future Schedule 13G/A filings would be required if HBM Healthcare Investments' beneficial ownership significantly changes (e.g., crosses a 1% threshold up or down, or falls below 5%).

Key Dates

Keywords

IO Biotech, HBM Healthcare Investments, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Biotech Investment, Institutional Investor